Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 The Academy of Model ... Aviation Day on August 15, 2015. National Model Aviation Day ... and to introduce model flying to the general public. , ... clubs to participate in the celebration by hosting events in ... host National Model Aviation Day events. View our online ...
(Date:5/28/2015)... 28, 2015 BioNorth Texas (BioNorthTX), ... representing the life sciences industry in northern region ... meeting at The Foundry in Dallas on April ... brought together a broad spectrum of biotech professionals ... organization's early successes in partnering with key life ...
(Date:5/28/2015)... May 28, 2015  GenVec, Inc. (Nasdaq: GNVC ... Douglas J. Swirsky , will present a company overview ... a.m. EDT on Thursday, June 4, 2015. ... presentation will be available at the following link:  ... GenVec,s website.  To access, visit www.genvec.com , click ...
(Date:5/28/2015)... 28, 2015 Whitehouse Laboratories is excited ... long term partnership with PTI Inspection Systems. Whitehouse Labs ... clients with custom-tailored method development and validation programs ... available. The agreement includes a more formal program that ... organizational lines. This enables a more effective team approach, ...
Breaking Biology Technology:Model flying pilots celebrate the Academy of Model Aeronautics Foundation’s Third Annual National Model Aviation Day 2BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3GenVec To Present At The Jefferies Healthcare Conference 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3
... Larson , Promega Corporation, Madison, WI, USA , ... Application Note 139 , ... , Multiplexing homogeneous cell-based assays for analysis of different , ... gene activity and cell viability , Assay miniaturization up to 1536-well format , ...
... impaction microbial assessment of your air supply may indicate you have unwanted ... RUDY PINA , ... Manufacturers of medical devices who label their product as sterile may use ... belts, and/or aseptic cleaning processes. The manufacturer may use these systems on ...
... Scanner 3000 , New ... , , ... The Affymetrix GeneChip Scanner 3000 design ... platform as an integrated genetic analysis system, supporting continued feature size ...
Cached Biology Technology:Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 2Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 3Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 4Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 5Testing Compressed Air Lines for Microbiological Contamination 2Testing Compressed Air Lines for Microbiological Contamination 3Testing Compressed Air Lines for Microbiological Contamination 4Testing Compressed Air Lines for Microbiological Contamination 5Testing Compressed Air Lines for Microbiological Contamination 6The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 2The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 3The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 4The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 5The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 6The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 7The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 8The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 9The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 10
(Date:5/21/2015)... DALLAS , May 21, 2015 ... report, "Thermal Imaging Market by Solutions (Hardware, Software, Services), ... Veterinary, Automotive & others), by End-Users (Military & ... published by MarketsandMarkets, Thermal Imaging Market is expected ... $9998.9 Million by 2020, at a Compound Annual ...
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... National Park in northwest India, one thing was hard for biologist ... jackals. It was the squawks of peacocks in the throes of ... could hear a loud two-part whoop, the distinctive call that male ... a male announces that he,s ready to make his move by ...
... many different types of chemicals and plastics for the ... these materials are provided from petrochemical industry, using fossil ... concerns on the environmental problems and fossil resource availability, ... and materials from renewable non-food biomass through biorefineries. For ...
... Cancer Center study in this month,s edition of the ... potential treatment for melanoma, the most dangerous form of skin ... are expressed and which stay silent. Melanoma tends to lack ... a double negative," says Yiqun Shellman, PhD, investigator at the ...
Cached Biology News:Peacock love songs lure eavesdropping females from afar 2Production of 5-aminovaleric and glutaric acid by metabolically engineered microorganism 2Serendipity points to new potential target and therapy for melanoma 2
Indoleamine 2,3-dioxygenase [IDO]...
... D7 F5] to RYK ( Abpromise ... Antigen: Synthetic peptide: ... amino acids 462 - 475 of ... ID: 6259 ...
Recognizes the 41 and 43 kDa G-proteins present in liver plasma membranes and Gq/11alpha expressed in the Sf9 insect cell expression system. Negative for recombinant G(I)alpha subtypes....
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: